All three treatment regimens, PARP inhibitor plus platinum (OR 0.8, 95% CI 0.65, 0.99), PARP inhibitor (OR 0.81 95% CI 0.68, 0.96), and platinum-based chemotherapy (OR 0.81 95% CI 0.65, 1.00), had a significantly lower risk of neutropenia than non-platinum-based chemotherapy. This evidence concerns the gene PARP1 and Decreased total neutrophil count.